Mannan-binding lectin (MBL) and MBL-associated serine protease-2 in children with cancer

Swiss Medical Weekly

Volumn 141, Issue APRIL, 2011, Pages

  Fischa, Urs P ^a   Zehndera, Aina ^a   Hirta, Andreas ^a   Nigglib, Felix K ^b   Simonc, Arne ^c   Ozsahind, Hulya ^d   Schlapbacha, Luregn J ^a   Ammanna, Roland A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cancer; Innate immunity; Lectin pathway of complement activation; Mannan binding lectin (MBL); MBL associated serine protease 2 (MASP 2)

Indexed keywords

MANNAN BINDING LECTIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNOSE BINDING LECTIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD LEVEL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SOLID TUMOR; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COMPLEMENT LECTIN PATHWAY; INNATE IMMUNITY; MEDICAL AUDIT; NEOPLASM; SWITZERLAND;

CHILD; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY, INNATE; MANNOSE-BINDING LECTIN; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; MEDICAL AUDIT; NEOPLASMS; RETROSPECTIVE STUDIES; SWITZERLAND;

EID: 79955800618     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13191     Document Type: Article

References (21)

1. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704-15.
2. Markiewsky MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009;30:286-92.
3. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol. 2007;44:3875-88. (Pubitemid 47337117)
4. Ytting H, Jensenius JC, Christensen IJ, Thiel S, Nielsen HJ. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol. 2004;39:674-9. (Pubitemid 38916245)
5. Baccarelli A, Hou L, Chen J, Lissowska J, El-Omar EM, Grillo P, et al. Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int J Cancer. 2006;119:1970-5. (Pubitemid 44356859)
6. Swierzko AS, Florczak K, Cedzyński M, Szemraj J, Wydra D, Bak-Romaniszyn L, et al. Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol Immunother. 2007;56:959-71.
7. Bernig T, Boersma BJ, Howe TM, Welch R, Yadavalli S, Staats B, et al. The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African-American and Caucasian women. Carcinogenesis. 2007;28:828-36. (Pubitemid 46523340)
8. Wang FY, Tahara T, Arisawa T, Shibata T, Yamashita H, Nakamura M, et al. Mannan-binding lectin (MBL) polymorphism and gastric cancer risk in Japanese population. Dig Dis Sci. 2008;53:2904-8.
9. Ytting H, Christensen IJ, Thiel S, Jensenius JC, Nielsen HJ. Serum mannan-binding lectin-associated serine protease 2 levels in colorectal cancer: relation to recurrence and mortality. Clin Cancer Res. 2005;15:1441-6. (Pubitemid 40315224)
10. Verma A, Matta A, Shukla NK, Deo SV, Gupta SD, Ralhan R. Clinical significance of mannose-binding lectinassociated serine protease-2 expression in esophageal squamous cell carcinoma. Int J Cancer. 2006;15:2930-5.
11. Schmiegelow K, Garred P, Lausen B, Andreassen B, Petersen BL, Madsen HO. Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia. Blood. 2002;15:3757-60. (Pubitemid 35303948)
12. Steliarova-Foucher E, Stiller CA, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103:1457-67. (Pubitemid 40410743)
13. Aittoniemi J, Miettinen A, Laippala P, Isolauri E, Viikari J, Ruuska T, Soppi E. Age-dependent variation in the serum concentration of mannan-binding protein. Acta Paediatr. 1996;85:906-9. (Pubitemid 27372308)
14. Sallenbach S, Thiel S, Aebi C, Otth M, Bigler S, Jensenius JC, et al. Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr Allergy Immunol. (in press, DOI 10.1111/j.1399-3038.2010.01104.x)
15. Ytting H, Christensen IJ, Thiel S, Jensenius JC, Svendsen MN, Nielsen L, et al. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand J Immunol. 2007;66:458-64. (Pubitemid 47394561)
16. Zehnder A, Fisch U, Hirt A, Niggli FK, Simon A, Ozsahin H, Schlapbach LJ, Ammann RA. Prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose-binding lectin-associated serine protease-2 (MASP-2). Pediatr Blood Cancer. 2009;53:53-7.
17. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225-35.
18. Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol. 1992;90:31-5.
19. Herpers BL, Endeman H, de Jong BA, de Jongh BM, Grutters JC, Biesma DH, van Velzen-Blad H. Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes. Clin Exp Immunol. 2009;156:488-94.
20. Schlapbach LJ, Aebi C, Otth M, Ridolfi Luethy A, Leibundgut K, Hirt A, Ammann RA. Serum levels of mannose-binding lectin and the risk of fever in neutropenic pediatric cancer patients. Pediatr Blood Cancer. 2007;49:11-6. (Pubitemid 46847063)
21. Gurney JG, Bondy ML. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, editors. Principles and practice in pediatric oncology, 5th ed. Philadelphia: Lippincott; 2006. p 1-13.